Specification

Product name:	Recombinant human LP-PLA2 antigen
Source:	*E.coli* derived
Accession #:	AAH38452.1
SDS-PAGE:	45 kDa, reducing conditions
Construction：	LP-PLA2 with 6His tag at N-terminal
Predicted Molecular Mass:	48.8kDa
Activity:	Immunoreactivity was confirmed by reacting with monoclonal antibodies specific to human LP-PLA2.
Application:	ELISA, immunology, others unspecified.
Form:	Liquid
Formulation:	20 mM Tris, 300 mM NaCl, pH 8.0
Stability & Storage:	Stable at -80°C
Shipping condition:	The product is shipped on ice pack.Upon receiving, store it immediately at the recommended temperature.
Conc. Determined:	BCA
Purity:	＞90%

SDS-PAGE



Greater than 90% as determined by reducing SDS-PAGE. (QC verified).

BACKGROUND

Platelet-Activating Factor Acetylhydrolase (PAFAH) is a secreted enzyme which belongs to the AB hydrolase superfamily and Lipase family and catalyzes the degradation of platelet-activating factor to biologically inactive products. PAFAH is produced by inflammatory cells and hydrolyzes oxidised phospholipids in LDL. PAFAH has been implicated in the development of atherosclerosis and has also been identified as a marker for cardiac disease. PAFAH might have a major physiologic effect in the presence of inflammatory bodily responses. PAFAH alters the action of PAF by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. PAFAH has specificity for substrates with a short residue at the sn-2 position.

References:

1. Libby P. The changing landscape of atherosclerosis. Nature. 2021 ; 592(7855):524-533.
2. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008 Feb 21;451(7181):904-13.
3. Lp-PLA(2) Studies Collaboration; Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 1;375(9725):1536-44. doi: 10.1016/S0140-6736(10)60319-4. PMID: 20435228; PMCID: PMC2864403.
4. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004 Feb 24;109(7):837-42. doi: 10.1161/01.CIR.0000116763.91992.F1. Epub 2004 Feb 2. PMID: 14757686.

Shenzhen Ruimeng Innovation Biotechnology Co., Ltd.
Room 1302-1305, 13F, Building D3, Nanshan Smart Park (Phase II),
No. 1001 Xueyuan Avenue, Nanshan District, Shenzhen City
Tel: +86 755 2616 5996
Web: www.rm-bio.com
PRC: 518055
Fax: +86 755 2616 5986
E-mail: rmi@rm-bio.com